Moebius Medical News
5 articles
/PRNewswire/ -- Sun Pharma (Reuters: SUN.BO) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715) (Sun Pharmaceutical Industries Limited, and includes its...
Sun Pharma and Moebius Medical have announced the publication of two peer-reviewed articles highlighting MM-II, a novel non-opioid product for treating symptomatic knee osteoarthritis. The articles, published in the journal Osteoarthritis and Cartilage, detail MM-IIs clinical efficacy and unique mechanism of action. A Phase 2b trial demonstrated that a single MM-II injection provided significant pain relief for up to 26 weeks. MM-II has been granted Fast Track Designation by the US FDA, underscoring its potential as a promising alternative to current treatments. The companies are presenting new data at the OARSI 2025 World Congress on Osteoarthritis. Moebius Medical is responsible for preclinical studies and product development through Phase 2, with Sun Pharma having the option to continue development and commercialization.
Product StagePartnersFDA approved/pending approval
/PRNewswire/ -- Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Limited, and includes its...
Sun Pharma and Moebius Medical announced that the FDA has granted Fast Track designation to their joint product MM-II for the treatment of osteoarthritis knee pain. This designation will facilitate the development and expedite the review process of MM-II, potentially bringing this new treatment to patients sooner. The companies are planning to initiate Phase 3 clinical trials and seek a CE Mark for the product in the European Union. MM-II is a novel non-opioid product designed to reduce joint pain by using a suspension of large liposomes. The Phase 2b study showed promising results, providing pain relief for up to 26 weeks.
Partners
Moebius Medical Announces FDA Clearance of IND Application for Phase IIb Clinical Trial of MM-II, a Novel Treatment for Knee Osteoarthritis Pain
Moebius Medical has received clearance from the US FDA to conduct a Phase IIb clinical trial for their candidate MM-II, which aims to treat pain in knee osteoarthritis. The trial will enroll 312 subjects and is expected to begin in the US, Europe, and Asia by the end of 2020. The primary endpoint is a reduction in pain from baseline, and top-line data is expected in mid-2022. MM-II is a non-opioid intra-articular injection that leverages proprietary liposomes and an innovative mechanism-of-action to provide sustainable relief. Moebius Medical is funded by RAD Biomed, PixVine Capital, and Yissum.
Investment
Israeli scientist could adapt shrimp antiviral for humans
Israeli scientist Avi Schroeder believes that an antiviral food additive developed for farmed shrimp could be adapted to protect humans against the coronavirus. The technology, developed by Schroeders lab and spun off into a startup called ViAqua Therapeutics, has proven effective in trials against viral diseases in shrimp. Schroeder believes that the same technology could be used to boost the immune system of humans against the coronavirus. In addition to ViAqua Therapeutics, Schroeder is involved in three other biotech startups: Peel Therapeutics, which focuses on using nanotechnology to deliver cancer medication; Moebius Medical, which has developed an injectable medication for severe osteoarthritis; and Barcode Diagnostics, which aims to help oncologists choose the best treatment for cancer patients. Schroeders lab at the Technion-Israel Institute of Technology is known for inventing disruptive technologies.
PartnersCustomers
Moebius, Sun sign osteoarthritis drug licensing deal
Moebius Medical has entered into a licensing deal with Sun Pharmaceutical Industries to develop MM-II, a non-opioid pharmaceutical candidate for the treatment of pain in osteoarthritis. The deal includes upfront payment, milestone payments, and royalties on sales. MM-II is an intra-articular biolubricant injection that aims to provide relief for osteoarthritis pain. Moebius Medical will handle pre-clinical studies and product development, while Sun Pharma will be responsible for clinical studies, regulatory submissions, and commercialization.
PartnersInvestment
